# An Open-Label Study to Enable Continued Treatment Access for Subjects Previously Enrolled in Studies of Ruxolitinib

> **NCT02955940** · PHASE2 · ACTIVE_NOT_RECRUITING · sponsor: **Incyte Corporation** · enrollment: 10 (actual)

## Conditions studied

- Pancreatic Cancer
- Colorectal Cancer (CRC)
- Breast Cancer
- Lung Cancer

## Interventions

- **DRUG:** Ruxolitinib
- **DRUG:** Capecitabine
- **DRUG:** Regorafenib

## Key facts

- **NCT ID:** NCT02955940
- **Lead sponsor:** Incyte Corporation
- **Sponsor class:** INDUSTRY
- **Phase:** PHASE2
- **Study type:** INTERVENTIONAL
- **Status:** ACTIVE_NOT_RECRUITING
- **Start date:** 2016-11-30
- **Primary completion:** 2027-09-30
- **Final completion:** 2027-09-30
- **Target enrollment:** 10 (ACTUAL)
- **Last updated:** 2025-12-17


## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT02955940

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT02955940, "An Open-Label Study to Enable Continued Treatment Access for Subjects Previously Enrolled in Studies of Ruxolitinib". Retrieved via AI Analytics 2026-07-15 from https://api.ai-analytics.org/clinical/NCT02955940. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*